Heart valve disease among patients with hyperprolactinemia: A nationwide population-based cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 5, 2012, Pages 1629-1634

  Steffensen, Charlotte ^a   Maegbaek, Merete Lund ^a   Laurberg, Peter ^b   Andersen, Marianne ^c   Kistorp, Caroline Micheala Nervil ^d   Norrelund, Helene ^e   Sorensen, Henrik Toft ^a   Jørgensen, Jens Otto Lunde ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Capital Region of Denmark   (Denmark)

^e VIBORG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN;

ADULT; AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; ARTICLE; ASYMPTOMATIC DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE REGISTRY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART VALVE SURGERY; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PATIENT SAFETY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK ASSESSMENT; SYSTEMATIC ERROR; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; FEMALE; FOLLOW-UP STUDIES; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84860773834     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3257     Document Type: Article

References (13)

1. Schlechte JA 2003 Prolactinoma. N Engl J Med 349:2035-2041
2. Schlechte JA 2007 Long term management of prolactinomas. J Clin Endocrinol Metab 92:2861-2865
3. Klibanski A 2010 Prolactinomas. N Engl J Med 362:1219-1226
4. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A 1999 Cabergoline in the treatment of hyperprolactinaemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518-2522
5. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
6. Zanettini R, Antonin IA, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
7. Kars M, Pereira AM, Bax JJ, Romijn JA 2008 Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur JEndocrinol 159:363-367
8. Valassi E, Klibanski A, Biller BM 2010 Potential cardiac valve effects of dopamine agonists in hyperprolactinaemia. J Clin Endocrinol Metab 95:1025-1033
9. Kar SM, Delgad OV, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM et al 2008 Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348-3356
10. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL 2008 Low dose of cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11-R14
11. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G 2008 Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777-3784
12. Choong C, Abascal VM, Weyman J, Levine RA, Gentile F, Thomas JD, Weyman AE 1989 Prevalence of valvular regurgitation by Doppler echo cardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J 117:636-642
13. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ 1999 Prevalence and clinical determinants of mitral, tricuspid and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897-902